Literature DB >> 19035978

Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands.

O S van Boxel1, M P Hagenaars, A J P M Smout, P D Siersema.   

Abstract

BACKGROUND: Chronic proton pump inhibitor (PPI) use is common in the Western world. Socio-economic status and socio-demographic factors have been shown to influence decisions related to prescribing of various drugs, but the influence of these factors on chronic PPI use is uncertain. AIM: To study the influence of SES and socio-demographic factors on chronic PPI use.
METHODS: Data were collected from a database of a Dutch health insurance company. Subjects having had at least one prescription for a PPI were identified and followed up for 6 months. Patients were then subdivided into chronic PPI users. Socio-demographic status was based on neighbourhood level of residence. Logistic regression was performed to determine socio-demographic factors associated with PPI use.
RESULTS: A total of 2 001 787 insured individuals were included, 85 253 subjects were chronic users. Both low income (OR 1.55; CI 1.52-1.58) and low educational level (OR 1.33; CI 1.31-1.36) were associated with chronic PPI use. Other independent predictive variables included use of 10 or more concomitant medications (OR 5.33; CI 4.96-5.72) and the use of prokinetic drugs (OR 10.01; CI 9.22-10.88).
CONCLUSIONS: Patients of a lower socio-demographic status are more likely to use PPIs on a chronic basis. The observed gradient in PPIs use may reflect differences in health, healthcare use or healthcare supply.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19035978     DOI: 10.1111/j.1365-2036.2008.03900.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Effects of proton pump inhibitor therapy in the distal gut: putting the pieces together.

Authors:  Daniel Keszthelyi; Ad A Masclee
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

2.  Many patients continue using proton pump inhibitors after negative results from tests for reflux disease.

Authors:  Andrew J Gawron; Jami Rothe; Angela J Fought; Anita Fareeduddin; Erin Toto; Lubomyr Boris; Peter J Kahrilas; John E Pandolfino
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-22       Impact factor: 11.382

Review 3.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

4.  Inhibition of lysosomal enzyme activities by proton pump inhibitors.

Authors:  Wensheng Liu; Susan S Baker; Jonathan Trinidad; Alma L Burlingame; Robert D Baker; John G Forte; Lauren P Virtuoso; Nejat K Egilmez; Lixin Zhu
Journal:  J Gastroenterol       Date:  2013-03-12       Impact factor: 7.527

5.  General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study.

Authors:  P F Haastrup; S Rasmussen; J M Hansen; R D Christensen; J Søndergaard; D E Jarbøl
Journal:  BMC Fam Pract       Date:  2016-05-28       Impact factor: 2.497

6.  Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation.

Authors:  Rajani Sharma; Abhik Roy; Christopher Ramos; Richard Rosenberg; Reuben Garcia-Carrasquillo; Benjamin Lebwohl
Journal:  Therap Adv Gastroenterol       Date:  2017-03-26       Impact factor: 4.409

7.  Patient Awareness of Reported Adverse Effects Associated with Proton Pump Inhibitors in a Medically Underserved Community.

Authors:  Brian White; Matthew Drew; John Gaughan; Sangita Phadtare
Journal:  Healthcare (Basel)       Date:  2020-11-19

8.  Assessment of Awareness and Knowledge of Proton Pump Inhibitors Among the General Population in Saudi Arabia.

Authors:  Emad S Aljahdli; Aseel M Mokhtar; Saad A Aljehani; Raad M Hamdi; Baraa H Alsubhi; Khaild F Aljuhani; Khaled A Saleh; Ammar D Alzoriri; Waleed S Alghamdi
Journal:  Cureus       Date:  2022-07-22

9.  Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study.

Authors:  Daniel Keszthelyi; Gwen H Dackus; Gwen M Masclee; Joanna W Kruimel; Ad A M Masclee
Journal:  BMC Gastroenterol       Date:  2012-09-05       Impact factor: 3.067

10.  Risk Factors for Sporadic Non-Pregnancy Associated Listeriosis in Germany-Immunocompromised Patients and Frequently Consumed Ready-To-Eat Products.

Authors:  Karina Preußel; Astrid Milde-Busch; Patrick Schmich; Matthias Wetzstein; Klaus Stark; Dirk Werber
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.